USSTOCK.TODAY
Market Closed
Log in Sign up

Cadrenal Therapeutics Inc(CVKD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today

CVKD
CVKD
Cadrenal Therapeutics Inc
At close Nov 19 at 4:00 PM ET (Korea 11/20 06:00)
$1.69
-0.03 ▼ -1.74%
Nov 19 at 7:46 PM ET (Korea 11/20 09:46)
$1.69
+0.00 +0.00%

Full metrics table

Index ⓘ -P/E ⓘ -EPS (ttm) ⓘ -3.9Insider Own ⓘ 9.66%Shs Outstand ⓘ 4.1MPerf Week ⓘ 11.92%
Market Cap ⓘ 0.01BForward P/E ⓘ -EPS next Y ⓘ 22.17%Insider Trans ⓘ -19.67%Shs Float ⓘ 3.7MPerf Month ⓘ 65.69%
Enterprise Value ⓘ 0.00BPEG ⓘ -EPS next Q ⓘ -0.91Inst Own ⓘ 10.41%Short Float ⓘ 6.2%Perf Quarter ⓘ 4.97%
Income ⓘ -0.01BP/S ⓘ -EPS this Y ⓘ 41.82%Inst Trans ⓘ 20.06%Short Ratio ⓘ 0.47Perf Half Y ⓘ -67.31%
Sales ⓘ 0.00BP/B ⓘ 2.36EPS next 5Y ⓘ 34.69%ROA ⓘ -267.9%Short Interest ⓘ 0.23MPerf YTD ⓘ -75.07%
Book/sh ⓘ 0.72P/C ⓘ 2.28EPS past 3/5Y ⓘ 8.46% -ROE ⓘ -358.34%52W High ⓘ -86.48% ($12.50)Perf Year ⓘ -84.99%
Cash/sh ⓘ 0.74P/FCF ⓘ -Sales past 3/5Y ⓘ -ROIC ⓘ -347.86%52W Low ⓘ 107.03% ($0.82)Perf 3Y ⓘ -75.83%
Dividend Est. ⓘ -EV/EBITDA ⓘ -EPS Y/Y TTM ⓘ 51.39%Gross Margin ⓘ -Volatility(W/M) ⓘ 18.18% 14.8%Perf 5Y ⓘ -
Dividend TTM ⓘ -EV/Sales ⓘ -Sales Y/Y TTM ⓘ -Oper. Margin ⓘ -ATR (14) ⓘ 0.18Perf 10Y ⓘ -
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 6.09EPS Q/Q ⓘ 76.62%Profit Margin ⓘ -RSI (14) ⓘ 65.99Recom ⓘ 1
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 6.09Sales Q/Q ⓘ -SMA20 ⓘ 35.91% ($1.24)Beta ⓘ 1.24Target Price ⓘ $14
Payout ⓘ -Debt/Eq ⓘ 0Earnings ⓘ 2026/8/13SMA50 ⓘ 50.34% ($1.12)Rel Volume ⓘ 0.08Prev Close ⓘ $1.72
Employees ⓘ 5LT Debt/Eq ⓘ 0EPS/Sales Surpr. ⓘ 19.72% -SMA200 ⓘ -52.14% ($3.53)Avg Volume(3M) ⓘ 0.49MPrice ⓘ $1.69
IPO ⓘ 2023/1/20Option/Short ⓘ No/YesTrades ⓘ 316Volume ⓘ 37,556Change ⓘ -1.74%
Company
CVKD CVKDCadrenal Therapeutics Inc | NASD | Biotechnology Deep dive

🩸 This is a small-cap U.S. biotech listed on NASDAQ that develops treatments for rare cardiovascular diseases, centered on Tecarfarin, an anticoagulant designed to deliver a more stable blood-thinning effect than the existing anticoagulant warfarin. The company is an ultra-small-cap listed firm expanding its clinical-stage pipeline, targeting specialized patient groups, including those with left ventricular assist devices (LVADs) and end-stage kidney disease (ESKD) patients with atrial fibrillation.

Quote

Over the past 1 year, on the lower side

86% below its 1-year high.

Now $1.69
52w low$0.8252w high$12.50
52W Range7%
Volume ⓘ 37,556

Traded less than usual. That is 8% of its average volume.

C
Overall · average, with some caution
We judged 6 of the 8 questions below. 1 rate excellent and 2 need caution.
No data for valuation, dividends, or not applicable.
ETFs holding this stock 4 ETFs

Multiple ETFs hold this stock, but only a sliver

Buying this ETF gives you exposure to this stock as well.

Peer comparison Biotechnology

It ranks #518 of 598 in the industry

Based on market cap of $7M.

FAQ

FAQ

What kind of company is CVKD?

CVKD belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of CVKD?

The market cap of CVKD is approximately $7M, ranking 5,466 within its sector.

What is the 52-week high and low for CVKD?

CVKD has recorded a 52-week high of $12.50 and a low of $0.82.

Telegram KakaoTalk
Briefs · earnings · signals, first Telegram · KakaoTalk channels